NCT07059299 - A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

Esophagogastric Junction AdenocarcinomaGastric AdenocarcinomaEsophageal AdenocarcinomaResectable Esophagogastric AdenocarcinomaNeoadjuvant Therapy

Interventions

DRUG

Tislelizumab

humanized immunoglobulin G4 (IgG4)-variant monoclonal antibody (mAb) against human programmed cell death-1 (PD-1)

DRUG

FLOT Chemotherapy

docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m² and 5-FU 2600 mg/m², all i.v. on day 1 Q2W

Trial Locations (1)

Universitätsklinikum Leipzig, Leipzig